Related Experiment Video
Updated: Apr 20, 2026
Author Spotlight: Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System
Published on: May 12, 2023
Cardiovascular news 2013/2014
J I Cuende1, C Lahoz2, P Armario3
1Servicio de Medicina Interna, Complejo Asistencial Universitario de Palencia, Palencia, España.
Insights
Recent cardiovascular research highlights PCSK-9 inhibitors for lipid lowering but questions nicotinic acid efficacy. Stent placement and sympathetic denervation show limited benefit for hypertension, while pharmacogenetic tests offer no warfarin advantage. Antiplatelet therapy may increase bleeding risk in atrial fibrillation patients.
Area of Science:
- Cardiology
- Vascular Medicine
- Metabolic Disorders
Background:
- Recent studies (2013-2014) address critical cardiovascular management areas.
- Evolving guidelines impact arterial hypertension and cholesterol reduction strategies.
- Emerging data contrasts PCSK-9 inhibitor efficacy with disappointing HDL-raising trials.
Purpose of the Study:
- To review recent advancements in cardiovascular medicine.
- To evaluate the clinical utility of new hypertension and lipid-lowering therapies.
- To assess antithrombotic strategies and lifestyle interventions for cardiovascular disease prevention.
Main Methods:
- Review of published cardiovascular studies from 2013-2014.
- Analysis of clinical trial data on lipid-lowering agents and hypertension interventions.
- Evaluation of evidence regarding antithrombotic treatments and dietary/surgical interventions.
Main Results:
- PCSK-9 inhibitors demonstrate significant lipid-lowering effects; nicotinic acid trials failed to reduce cardiovascular events.
- Stent placement and sympathetic denervation are ineffective for renovascular and resistant hypertension.
- Pharmacogenetic testing offers no clear benefit for warfarin anticoagulation; antiplatelet therapy may increase bleeding risk in atrial fibrillation patients.
- Mediterranean diet and bariatric surgery show potential for diabetes prevention and management.
Conclusions:
- PCSK-9 inhibitors represent a promising advance in lipid management.
- Current interventional strategies for hypertension lack proven efficacy.
- Optimizing antithrombotic therapy and considering lifestyle interventions are crucial for patient care.
Abstract:
During 2013 and the first months of 2014, numerous studies have been published in the cardiovascular field. New guidelines have appeared for managing arterial hypertension and reducing cardiovascular risk by lowering cholesterol levels. New data have emerged on the considerable lipid-lowering efficacy of monoclonal antibodies against PCSK-9, in contrast, however, to the clinical trials directed towards raising HDL-cholesterol with nicotinic acid, which have not shown a reduction in the rate of cardiovascular complications. In the field of hypertension, neither stent placement in patients with renovascular hypertension nor sympathetic denervation in patients with resistant hypertension has been shown to be effective in reducing blood pressure. In terms of antithrombotic treatment, the pharmacogenetic tests do not seem useful for maintaining patients anticoagulated with warfarin within the therapeutic range for longer periods. Moreover, there is increasing evidence that, for patients with coronary artery disease and atrial fibrillation, antiplatelet therapy adds no benefit to anticoagulation therapy and is associated with a greater risk of bleeding. Lastly, a Mediterranean diet could prevent the onset of diabetes, while bariatric surgery could be a reasonable option for improving the disease in patients with obesity. Many of these studies have immediate practice applications in daily clinical practice.
Related Concept Videos
01:27Regulation of the Cardiovascular System
The regulation of the cardiovascular system involves the autonomic nervous system (ANS), baroreceptors, and chemoreceptors, ensuring that heart rate and blood pressure are appropriately modulated in response to varying physiological demands.
The ANS comprises two main divisions: the sympathetic and parasympathetic nervous systems. The sympathetic nervous system enhances...
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
01:29Cardiomyopathy V: Interprofessional Care
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
01:27Peripheral Artery Disease III: Interprofessional Care
01:14Overview of the Cardiovascular System
Heart
The heart is the central pump of the cardiovascular system that circulates blood throughout the body. It comprises two atria receiving the blood and two ventricles pumping blood out of the heart. Their rhythmic contractions, called heartbeats, ensure that blood flow remains continuous.
Blood Vessels
Blood...